Edwards Lifesciences Inkomsten in het verleden
Verleden criteriumcontroles 4/6
Edwards Lifesciences is de winst gegroeid met een gemiddeld jaarlijks percentage van 11.3%, terwijl de Medical Equipment industrie de winst jaarlijks groeide met 13.3%. De inkomsten zijn gegroeid met een gemiddelde snelheid van 7.8% per jaar. Het rendement op eigen vermogen van Edwards Lifesciences is 16.3%, en het heeft een nettomarge van 24.8%.
Belangrijke informatie
11.3%
Groei van de winst
12.0%
Groei van de winst per aandeel
| Medical Equipment Groei van de industrie | 8.9% |
| Inkomstengroei | 7.8% |
| Rendement op eigen vermogen | 16.3% |
| Nettomarge | 24.8% |
| Laatste winstupdate | 30 Sep 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Edwards Lifesciences Q3: Divesting Critical Care And Focusing On Structural Hearts
Oct 25Bearish: Analysts Just Cut Their Edwards Lifesciences Corporation (NYSE:EW) Revenue and EPS estimates
Sep 11
Capital Investments At Edwards Lifesciences (NYSE:EW) Point To A Promising Future
Aug 30Is Now The Time To Look At Buying Edwards Lifesciences Corporation (NYSE:EW)?
Aug 17Edwards Lifesciences Q2: Buy The Dip Amid Guidance Cut
Jul 26Calculating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)
Jul 26Why Investors Shouldn't Be Surprised By Edwards Lifesciences Corporation's (NYSE:EW) P/E
Jul 12Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?
Jun 24Edwards Lifesciences Corp Looks Bullish (Technical Analysis)
Jun 22Capital Investments At Edwards Lifesciences (NYSE:EW) Point To A Promising Future
May 13Edwards Lifesciences: EPS Acceleration, Shares Poised To Rally (Rating Upgrade)
May 09When Should You Buy Edwards Lifesciences Corporation (NYSE:EW)?
Apr 29Calculating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)
Apr 15Edwards Lifesciences Corporation's (NYSE:EW) Popularity With Investors Is Clear
Apr 01Edwards Lifesciences' (NYSE:EW) Soft Earnings Don't Show The Whole Picture
Feb 21Edwards Lifesciences: EVOQUE FDA Approval; Critical Care Spin-Off (Rating Maintained)
Feb 14Edwards Lifesciences Corporation (NYSE:EW) Released Earnings Last Week And Analysts Lifted Their Price Target To US$90.47
Feb 08Here's Why Edwards Lifesciences (NYSE:EW) Can Manage Its Debt Responsibly
Jan 28The Returns At Edwards Lifesciences (NYSE:EW) Aren't Growing
Jan 14Edwards Lifesciences: Undervalued With A Substantial Upside Potential
Jan 09Edwards Lifesciences Corporation's (NYSE:EW) Share Price Not Quite Adding Up
Dec 31Calculating The Fair Value Of Edwards Lifesciences Corporation (NYSE:EW)
Dec 17Edwards Lifesciences: Sector Derating A Bigger Threat Than Competition Or Slowing Markets
Oct 26Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?
Oct 23Is Now The Time To Look At Buying Edwards Lifesciences Corporation (NYSE:EW)?
Oct 09Edwards Lifesciences (NYSE:EW) Is Reinvesting To Multiply In Value
Sep 26A Look At The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)
Sep 11Edwards Lifesciences: Rising Dominance In Structural Heart Disease
Aug 21Opbrengsten en kosten
Hoe Edwards Lifesciences geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Sep 24 | 6,315 | 1,567 | 1,955 | 1,133 |
| 30 Jun 24 | 6,204 | 1,540 | 1,915 | 1,122 |
| 31 Mar 24 | 6,114 | 1,428 | 1,874 | 1,095 |
| 31 Dec 23 | 6,005 | 1,402 | 1,823 | 1,072 |
| 30 Sep 23 | 5,092 | 1,288 | 1,576 | 953 |
| 30 Jun 23 | 5,168 | 1,296 | 1,571 | 944 |
| 31 Mar 23 | 5,279 | 1,451 | 1,578 | 951 |
| 31 Dec 22 | 5,382 | 1,522 | 1,567 | 945 |
| 30 Sep 22 | 5,364 | 1,459 | 1,581 | 946 |
| 30 Jun 22 | 5,355 | 1,455 | 1,568 | 950 |
| 31 Mar 22 | 5,357 | 1,539 | 1,534 | 925 |
| 31 Dec 21 | 5,233 | 1,503 | 1,494 | 903 |
| 30 Sep 21 | 5,095 | 1,477 | 1,409 | 866 |
| 30 Jun 21 | 4,925 | 1,462 | 1,351 | 824 |
| 31 Mar 21 | 4,474 | 851 | 1,252 | 780 |
| 31 Dec 20 | 4,386 | 823 | 1,229 | 761 |
| 30 Sep 20 | 4,369 | 794 | 1,235 | 759 |
| 30 Jun 20 | 4,322 | 744 | 1,234 | 759 |
| 31 Mar 20 | 4,484 | 1,108 | 1,268 | 769 |
| 31 Dec 19 | 4,348 | 1,047 | 1,242 | 753 |
| 30 Sep 19 | 4,152 | 774 | 1,182 | 722 |
| 30 Jun 19 | 3,964 | 725 | 1,146 | 688 |
| 31 Mar 19 | 3,821 | 765 | 1,113 | 650 |
| 31 Dec 18 | 3,723 | 722 | 1,088 | 622 |
| 30 Sep 18 | 3,634 | 712 | 1,080 | 606 |
| 30 Jun 18 | 3,549 | 657 | 1,055 | 587 |
| 31 Mar 18 | 3,447 | 560 | 1,023 | 567 |
| 31 Dec 17 | 3,435 | 584 | 984 | 553 |
| 30 Sep 17 | 3,315 | 745 | 948 | 521 |
| 30 Jun 17 | 3,232 | 716 | 933 | 491 |
| 31 Mar 17 | 3,150 | 657 | 918 | 469 |
| 31 Dec 16 | 2,964 | 570 | 905 | 442 |
| 30 Sep 16 | 2,867 | 552 | 892 | 426 |
| 30 Jun 16 | 2,743 | 528 | 875 | 414 |
| 31 Mar 16 | 2,601 | 515 | 860 | 399 |
| 31 Dec 15 | 2,494 | 495 | 851 | 383 |
| 30 Sep 15 | 2,441 | 463 | 852 | 369 |
| 30 Jun 15 | 2,433 | 440 | 862 | 356 |
| 31 Mar 15 | 2,391 | 874 | 863 | 347 |
| 31 Dec 14 | 2,323 | 811 | 858 | 347 |
| 30 Sep 14 | 2,241 | 777 | 822 | 341 |
| 30 Jun 14 | 2,129 | 759 | 777 | 338 |
| 31 Mar 14 | 2,071 | 306 | 748 | 329 |
| 31 Dec 13 | 2,046 | 389 | 733 | 323 |
Kwaliteitswinsten: EW heeft hoge kwaliteitsinkomsten.
Groeiende winstmarge: De huidige netto winstmarges (24.8%) EW } zijn lager dan vorig jaar (25.3%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: De winst van EW is de afgelopen 5 jaar met 11.3% per jaar gegroeid.
Versnelling van de groei: De winstgroei van EW over het afgelopen jaar ( 21.7% ) overtreft het 5-jarig gemiddelde ( 11.3% per jaar).
Winst versus industrie: De winstgroei EW over het afgelopen jaar ( 21.7% ) overtrof de Medical Equipment -sector 12.2%.
Rendement op eigen vermogen
Hoge ROE: Het Rendement op eigen vermogen ( 16.3% ) van EW wordt als laag beschouwd.